Difference between revisions of "BL22 immunotoxin (CAT-3888)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "www.ncbi.nlm.nih.gov/pubmed" to "pubmed.ncbi.nlm.nih.gov") |
m |
||
(8 intermediate revisions by 2 users not shown) | |||
Line 2: | Line 2: | ||
==General information== | ==General information== | ||
− | Class/mechanism: Recombinant anti-CD22 immunotoxin fusion protein comprised of a murine anti-CD22 antibody fragment (disulphide-linked Fv, dsFv) and Pseudomonas exotoxin PE38. | + | Class/mechanism: Recombinant anti-CD22 immunotoxin fusion protein comprised of a murine anti-CD22 antibody fragment (disulphide-linked Fv, dsFv) and Pseudomonas exotoxin PE38. BL22 binds to CD22 positive cells and is endocytosed, resulting in intracellular release of the toxin and cell death. |
− | The original manufacturer was acquired in 2005.<ref>[http://www.biospace.com/news_print.aspx?NewsEntityId=1132 Cambridge Antibody Technology Group PLC | + | The original manufacturer was acquired in 2005.<ref>[http://www.biospace.com/news_print.aspx?NewsEntityId=1132 Cambridge Antibody Technology Group PLC (CATG) Acquires Oncology Product Candidates From Genencor International, Inc.]</ref> Development of this drug was discontinued in 2008, at which time it was superseded by the more potent and less toxic [[Moxetumomab pasudotox (HA22)]]. |
==Preliminary data== | ==Preliminary data== | ||
===[[Hairy cell leukemia]]=== | ===[[Hairy cell leukemia]]=== | ||
− | # Kreitman RJ, Wilson WH, Bergeron K, Raggio M, Stetler-Stevenson M, FitzGerald DJ, Pastan I. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N Engl J Med. 2001 Jul 26;345(4):241-7. [https:// | + | # Kreitman RJ, Wilson WH, Bergeron K, Raggio M, Stetler-Stevenson M, FitzGerald DJ, Pastan I. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N Engl J Med. 2001 Jul 26;345(4):241-7. [https://doi.org/10.1056/NEJM200107263450402 link to original article] [https://pubmed.ncbi.nlm.nih.gov/11474661/ PubMed] |
− | # Kreitman RJ, Stetler-Stevenson M, Margulies I, Noel P, Fitzgerald DJ, Wilson WH, Pastan I. Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia. J Clin Oncol. 2009 Jun 20;27(18):2983-90. Epub 2009 May 4. [ | + | # Kreitman RJ, Stetler-Stevenson M, Margulies I, Noel P, Fitzgerald DJ, Wilson WH, Pastan I. Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia. J Clin Oncol. 2009 Jun 20;27(18):2983-90. Epub 2009 May 4. [https://doi.org/10.1200/jco.2008.20.2630 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc2702232/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/19414673/ PubMed] |
==Also known as== | ==Also known as== | ||
Line 20: | Line 20: | ||
[[Category:Intravenous medications]] | [[Category:Intravenous medications]] | ||
− | + | ||
[[Category:Immunotoxin]] | [[Category:Immunotoxin]] | ||
− | [[Category:Anti-CD22 | + | [[Category:Anti-CD22 immunotoxins]] |
+ | [[Category:Recombinant medications]] | ||
+ | |||
[[Category:Halted drugs]] | [[Category:Halted drugs]] |
Latest revision as of 14:33, 28 February 2024
No longer in clinical development. Related to GCR-8015/CAT-8015, which have increased affinity to CD22.
General information
Class/mechanism: Recombinant anti-CD22 immunotoxin fusion protein comprised of a murine anti-CD22 antibody fragment (disulphide-linked Fv, dsFv) and Pseudomonas exotoxin PE38. BL22 binds to CD22 positive cells and is endocytosed, resulting in intracellular release of the toxin and cell death.
The original manufacturer was acquired in 2005.[1] Development of this drug was discontinued in 2008, at which time it was superseded by the more potent and less toxic Moxetumomab pasudotox (HA22).
Preliminary data
Hairy cell leukemia
- Kreitman RJ, Wilson WH, Bergeron K, Raggio M, Stetler-Stevenson M, FitzGerald DJ, Pastan I. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N Engl J Med. 2001 Jul 26;345(4):241-7. link to original article PubMed
- Kreitman RJ, Stetler-Stevenson M, Margulies I, Noel P, Fitzgerald DJ, Wilson WH, Pastan I. Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia. J Clin Oncol. 2009 Jun 20;27(18):2983-90. Epub 2009 May 4. link to original article link to PMC article PubMed
Also known as
- Code names: CAT-3888, GCR-3888